Growth Opportunities in the US Prenatal Genetic Testing Market, Forecast to 2021

Rising Maternal Age, Improved Screening Algorithms Catering to Healthcare Payer Requirements, and Exploration of New Business Models Will Drive Market Growth
Share this:
Published: 21 Jul 2017

Prenatal genetic tests, which are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, and 13, and carrier screens, are gaining momentum in the United States due to enhanced assay outcomes through non-invasive methodologies, increased popularity through social media channels, and the growing number of women choosing to undergo pregnancy at an advanced maternal age. The growth in demand has led to a high level of merger and acquisition activity, apart from numerous collaborations, which in turn has bolstered the product portfolio of several companies in the women’s healthcare segment. With this accelerated growth, companies are exploring new avenues to market their products, thereby strategically tying up with IVF clinics, physicians, and OBGYNs. New business models like direct to consumer (DTC) are seeing increased uptake due to ease of use and hassle-free processing. Partnerships with Big Data companies will be the next big leap in the prenatal genetic testing market, thereby providing interpretation of vast volumes of data to increase specificity and sensitivity. Research Scope: The key objectives of this growth opportunity study are to track the changes in the prenatal genetic testing market landscape in the United States from 2016 to 2021. The study aims to identify growth segments and disruptive companies for investment. Further, it provides an in-depth revenue and market share analysis of 4 key segments, namely, NIPT, carrier screening for cystic fibrosis, invasive tests, and miscarriage tests. The study highlights industry challenges, growth drivers and restraints, competitive developments, mergers and acquisitions, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA) and the LDT guidelines issued by the FDA, identifies transforming business models, and makes strategic recommendations to understand market dynamics. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies, and strategic recommendations. Key questions this study will answer include: What are the long-term growth prospects in the market? What are the other areas of growth outside NIPT? What are the opportunities to explore in carrier screening and miscarriage screening? What are some of the innovative companies to action and to follow? How should you price your tests to remain competitive in the market? Who are the established market participants and what are their strategies to remain competent in this market?



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..